Teva Pharmaceutical at Decade High – 33% Brand Growth and New Approval Opportunities!

Three important branded drugs grow together by 33%. WELTRUZA and UZEDY together offer up to $2 billion in revenue potential. Higher margins, upgraded forecasts, and a research day provide momentum. Teva Pharmaceutical Industries (TEVA) is transforming from a generic drug manufacturer to a pharmaceutical company more focused on its own medications. The stock reached a decade high of $43.34 on November 3rd. Since the beginning of the year, the increase is about 37%. The operational trend reversal is clear: generics are under price pressure,...